Anti-MDA5 antibodies occur at a high level in patients with CADM, not only affecting the symptoms and prognosis of DM but also having a non-negligible impact on the differences between CADM and CDM. This evidence concerns the gene IFIH1 and clinically amyopathic dermatomyositis.